Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis

Antiviral Therapy

Volumn 9, Issue 1, 2004, Pages 57-65

  Witvrouw, Myriam ^a   Pannecouque, Christophe ^a   Switzer, William M ^b   Folks, Thomas M ^b   De Clercq, Erik ^a   Heneine, Walid ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG USE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; CONSENSUS SEQUENCE; HIV; HIV-1 REVERSE TRANSCRIPTASE; HIV-2; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 1542319002     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mukhopadhyay C, Nath G, Gulati AK & Mohapatra SC. Prevalence of HIV among low and high risk population of eastern part of northern India. Journal of Communicable Diseases 2001; 33:136-142.
2. Quiros-Roldan E, Castelli F, Pan A, Chiodera S, Casari S, Airoldi M & Carosi G. Evidence of HIV-2 infection in northern Italy. Infection 2001; 29:362-363.
3. Shamugam V, Switzer WM, Nkengasong JN, Garcia-Lerma G, Green T, Ekpini E, Sassan-Morokro M, Antunes F, Manshino K, Soriano V, Wiktor S & Heneine W. Lower HIV-2 plasma viral loads may explain the differences between the natural histories of HIV-1 and HIV-2 infections. Journal of Acquired Immune Deficiency Syndromes 2000; 24:257-263.
4. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI & Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proceedings of the National Academy of Sciences, USA 2002; 99:14410-14415.
5. Rabaud C, Bevilacqua S, Beguinot I, Dorvaux V, Schuhmacher H, May T & Canton P. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clinical Infectious Diseases 2001; 32:1494-1495.
6. Khabbaz RF, Heneine W, George JR, Parekh B, Rowe T, Woods T, Switzer WM, McClure HM, Murphey-Corb M & Folks TM. Infection of a laboratory worker with simian immunodeficiency virus. New England Journal of Medicine 1994; 330:172-177.
7. Khabbaz RF, Rowe T, Murphey-Corb M, Heneine WM, Schable CA, George JR, Pau CP, Parekh BS, Lairmore MD, Curran JW et al. Simian immunodeficiency virus needlestick in a laboratory worker. Lancet 1992; 340:271-273.
8. Horwitz JP, Chua J & Noel M. Nucleoside V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymine. Journal of Organic Chemistry 1964; 29:2076-2078.
9. Popovic M, Sarngadharan MG, Read E & Gallo RC. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224:497-500.
10. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W & Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science 1983; 220:868-871.
11. Rey MA, Krust B, Laurent AG, Guétard D, Montagnier L & Hovanessian AG. Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein. Virology 1989; 173:258-267.
12. Daniel MD, Letvin NL, Sehgal PK, Hunsmann G, Schmidt DK, King NW & Desrosiers RC. Long-term persistent infection of macaque monkeys with simian immunodeficiency virus. Journal of General Virology 1987; 68:3183-3189.
13. Conway MD, Davison-Fairburn B, Martin LN, Insler MS & Murphey-Corb M. Infection of rhesus monkeys with topical instillation of simian immunodeficiency virus (SIV)B670 into the conjunctival sac. Journal of Medical Primatology 1991; 20:152-155.
14. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, Lin W, Montefiori DC, Lee-Parritz DE, Lu Y, Collman RG, Sodroski J & Letvin NL. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. Journal of Virology 1996; 70:3198-3206.
15. Reimann KA, Li JT, Veazy R, Halloran M, Park IW, Karlsson GB, Sodroski J & Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. Journal of Virology 1996; 70:6922-6928.
16. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G & Oberg B. Animal Model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proceedings of the National Academy of Sciences, USA 1995; 92:8210-8214.
17. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 1998; 20:309-321.
18. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A & Martin MA. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology 1986; 59:284-291.
19. Spire B, Sire J, Zachar V, Rey F, Barre-Sinoussi F, Galibert F, Hampe A & Chermann JC. Nucleotide sequence of HIV-1-NDK: a highly cytopathic strain of human immunodeficiency virus. Gene 1989; 81:275-284.
20. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500-503.
21. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme A-M, Janssen CGM, Anné J, Cauwenbergh G, Desmyter J, Heykants J, Janssen MAC, De Clercq E & Janssen PAJ. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alfa-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:1711-1715.
22. Schmit J-C, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, Witvrouw M, Balzarini J, Desmyter J, De Clercq E & Vandamme A-M. Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. Journal of Infectious Diseases 1996; 174:962-968.
23. Deeks SG. International perspectives on antiretroviral resistance. Non-nucleoside reverse transcriptase inhibitor resistance. Journal of Acquired Immune Deficiency Syndromes 2001; 26:S25-S33.
24. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT & Martinez-Picado J. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002; 16:1009-1017.
25. Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, Elston R, Yeo J, Randall S, Xu F, Parker H, May J & Snowden W. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrobial Agents & Chemotherapy 2002; 46:731-738.
26. Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J & Tisdale M. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antiviral Therapy 2003; 8:111-120.
27. Watkins T, Resch W, Irlbeck D & Swanstrom R. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrobial Agents & Chemotherapy 2003; 47:759-769.
28. Rimsky LT, Shugars DC & Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. Journal of Virology 1998; 72:986-993.
29. Rosenblum LL, Patton G, Grigg AR, Frater AJ, Cain D, Erlwein O, Hill CL, Clarke JR & McClure MO. Differential susceptibility of retroviruses to nucleoside analogues. Antiviral Chemistry & Chemotherapy 2001; 12:91-97.
30. Giuffre AC, Higgins J, Buckheit RW Jr & North TW. Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrobial Agents & Chemotherapy 2003; 47:1756-1759.
31. Molino M, Woolkalis MJ, Prevost N, Pratico D, Barnathan ES, Taraboletti G, Haggarty BS, Hesselgesser J, Horuk R, Hoxie JA & Brass LF. CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. Biochimical & Biophysical Acta 2000; 1500:227-240.
32. Heil M, Decker J, T-Chen D, Sfakianos J, Shaw G, Hunter E & Derdeyn C. Analysis of patient-derived HIV-1 isolates suggests a novel mechanism for decreased sensitivity to inhibition by enfuvirtide and T-649. 10th Conference on Retroviruses & Opportunistic Infections. Boston, Mass., USA, 10-14 February 2003; 615:278.
33. Clark NM, Dieng Sarr A, Sankale JL, Kanki PJ, Kazanjian P, Winfield R & Markovitz DM. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy. AIDS 1998; 12:2506-2507.
34. Schutten M, van der Ende ME & Osterhaus AD. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. New England Journal of Medicine 2000; 342:1758-1760.